Friday, November 22, 2024 11/22/2024

Examining Modifiable Psychosocial Predictors of HIV Seroconversion in a Large Nationwide Cohort of High Risk Men

Award Number: UH3AI133674
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary Gay, bisexual and other men who have sex with men (GBMSM) remain a population in the U.S. for whom the burden of HIV is high and disproportionate, particularly among younger GBMSM and GBMSM of color, for whom HIV incidence continues to rise despite decades of HIV prevention research to curb the epidemic. However, even among these highest risk groups, risk for infection is not equivalent and the goal of this study is to better understand what factors differentiate levels of risk for HIV infection. Research to date suggests that this disproportionate burden is likely to be exacerbated by psychosocial disparities faced by this population in the form of syndemics and sexual minority stress. However, research on these factors has been limited by a focus on risk for HIV infection operationalized as risk behavior or cross-sectional prevalence of HIV, making actual vulnerability to infection and temporal associations difficult, if not impossible, to determine. We are submitting this application in response to RFA-AI-16-031 Limited Interaction Targeted Epidemiology (LITE) to Advance HIV Prevention (UG3/UH3). We propose to recruit and enroll a large and diverse cohort of approximately 8,000 GBMSM ages 16 and older in the U.S. and Puerto Rico who are at high risk for infection. We will utilize mobile sexual networking applications (“mobile apps”) to identify and enroll these men both to allow for rapid and efficient recruitment and because these apps rapidly increasing in popularity, with research demonstrating that men who use mobile apps are at higher levels of risk for HIV infection than GBMSM recruited through other means. Using this cohort, we will work to achieve three primary aims: (1) we will establish HIV prevalence as well as prevalence of rectal sexually transmitted infections (STIs; gonorrhea and chlamydia) at baseline and subsequently establish rates of HIV and rectal STI incidence among these men 12 months thereafter; (2) we will utilize baseline levels of syndemic, minority stress, and other relevant psychosocial risk factors to develop a model of those modifiable factors that contribute to increased risk for HIV seroconversion (i.e., incidence) as well as rectal STI infection; (3) we will utilize the model to target men in the highest quartile of risk for HIV seroconversion in the cohort and follow them every 6 months thereafter for an additional two years to examine the predictive utility in prospectively predicting HIV seroconversion as well as time to seroconversion. Developing a model of modifiable psychosocial risk factors for actual HIV seroconversion and subsequently testing its reliability and validity in a prospective design has high potential to improve the next generation of HIV prevention interventions aimed at reducing disparities for this population.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	WHITMAN-WALKER INSTITUTE INC	1525 14TH ST NW	WASHINGTON	DC	20005	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	000	5	7/11/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $7,305 )
2022	2021	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	002	5	5/9/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$7,305
2022	2021	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	001	5	2/14/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$358,194
2022	2021	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	003	5	7/26/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2022	2020	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	000	4	2/14/2022	NON-COMPETING CONTINUATION	-$358,194
														Subtotal = $7,305

Issue Date FY: 2021 ( Subtotal = $860,533 )
2021	2021	WHITMAN-WALKER INSTITUTE, INC.	1377 R ST NW STE 200	WASHINGTON	DC	20009	DISTRICT OF COLUMBIA	USA	Allergy and Infectious Diseases Research	001	5	8/5/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$860,533
2021	2020	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	000	4	8/5/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $860,533

Issue Date FY: 2020 ( Subtotal = $1,874,498 )
2020	2020	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	006	4	8/21/2020	SUPPLEMENT FOR EXPANSION	$158,153
2020	2020	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	005	4	7/30/2020	NON-COMPETING CONTINUATION	$0
2020	2020	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	004	4	7/22/2020	NON-COMPETING CONTINUATION	$1,536,639
2020	2019	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	002	3	4/10/2020	EXTENSION WITH OR WITHOUT FUNDS	$0
2020	2019	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	003	3	7/21/2020	EXTENSION WITH OR WITHOUT FUNDS	$0
2020	2019	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	000	3	3/25/2020	EXTENSION WITH OR WITHOUT FUNDS	$179,706
2020	2019	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	001	3	4/2/2020	EXTENSION WITH OR WITHOUT FUNDS	$0
														Subtotal = $1,874,498

Issue Date FY: 2019 ( Subtotal = $1,372,892 )
2019	2019	RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK	695 PARK AVE	NEW YORK	NY	10065	NEW YORK	USA	Allergy and Infectious Diseases Research	000	3	7/31/2019	EXTENSION WITH OR WITHOUT FUNDS	$1,372,892
														Subtotal = $1,372,892

Grand Total All Awards = $4,115,228

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Examining Modifiable Psychosocial Predictors of HIV Seroconversion in a Large Nationwide Cohort of High Risk Men

Award Number: UH3AI133674

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer